Evolent Health, Inc
Description
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
About
CEO
Mr. Seth Barrie Blackley
Employees
4,700
Instrument type
Common Stock
Sector
Healthcare
Industry
Health Information Services
MIC code
XNYS
Address
1812 N. Moore Street, Arlington, VA 22209, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 5, 2025 | — | — | — | — |
| Aug 7, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Feb 21, 2025 | 0.38 | — | — | — |
| Nov 8, 2024 | 0.34 | 0.04 | -0.30 | -88.24% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 9 | — | 11 |
| Average estimate | — | 0.16 | — | 0.75 |
| Low estimate | — | 0.12 | — | 0.45 |
| High estimate | — | 0.20 | — | 0.98 |
| Last year EPS | — | 0.34 | — | 0.72 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-91.670%
Next qtr. (Mar 2025)
-51.830%
Current year
-17.580%
Next year (Dec 2025)
-4.080%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.96B | 1.35B | 907.96M | 924.64M | 687.12M |
| Cost of revenue | 1.50B | 1.04B | 657.55M | 696.58M | 513.03M |
| Gross profit | 460.47M | 316.58M | 250.41M | 228.06M | 174.09M |
| Operating expense | |||||
| Research & development | — | — | — | — | — |
| Selling general and admin | 358.11M | 269.27M | 219.50M | 210.41M | 236.45M |
| Other operating expenses | — | — | — | — | 135.77M |
| Operating income | -21.06M | -19.88M | -29.13M | -43.19M | -122.68M |
| Non operating interest income | |||||
| Income | 5.26M | 1.37M | 407,000 | 2.63M | 3.41M |
| Expense | 54.21M | 15.57M | 25.43M | 28.33M | 14.56M |
| Other income expense | -132.40M | -27.99M | 24.35M | -261.66M | -196.16M |
| Pretax income | -202.41M | -62.08M | -29.80M | -330.54M | -329.99M |
| Tax provision | -89.37M | -43.38M | 483,000 | -2.37M | -22.80M |
| Net income | -113.04M | -19.16M | -37.60M | -334.25M | -305.58M |
| Basic EPS | -1.28 | -0.20 | -0.44 | -3.94 | -3.67 |
| Diluted EPS | -1.28 | -0.20 | -0.44 | -3.94 | -3.67 |
| Basic average shares | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M |
| Diluted average shares | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M |
| EBITDA | 46.38M | 7.36M | 90.29M | 30.84M | -68.32M |
| Net income from continuing op. | -113.04M | -19.16M | -37.60M | -334.25M | -305.58M |
| Minority interests | — | — | — | — | 3.61M |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2.68B | 1.82B | 1.42B | 1.37B | 1.50B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 192.83M | 188.20M | 266.28M | 319.00M | 101.01M |
| Other short term investments | — | — | — | 3.86M | 1.81M |
| Accounts receivable | 446.75M | 254.68M | 130.60M | 124.06M | 75.67M |
| Other receivables | — | — | — | 329,000 | 1.75M |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 51.39M | 56.30M | 28.49M |
| Restricted cash | 13.77M | 14.49M | 75.69M | 14.37M | 20.08M |
| Assets held for sale | — | — | — | 33.91M | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 30.33M | 20.68M | 51.39M | — | — |
| Non current assets | |||||
| Properties | 11.98M | 49.03M | 50.20M | 57.80M | 72.17M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 22.80M | 34.31M | 25.55M | 22.43M | 15.25M |
| Construction in progress | 212.91M | 189.12M | 159.59M | 137.09M | 112.50M |
| Leases | 1.05M | 14.93M | 15.33M | 15.59M | 12.42M |
| Accumulated depreciation | -158.57M | -150.48M | -119.10M | -88.86M | -55.01M |
| Goodwill | 2.99B | 1.89B | 1.13B | 963.05M | 1.45B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 752.01M | 442.78M | 279.78M | 264.99M | 308.46M |
| Investments and advances | 4.90M | 4.48M | 5.46M | 6.50M | 139.37M |
| Other non current assets | 33.01M | 32.31M | 52.39M | 53.72M | 45.74M |
| Total liabilities | 1.61B | 957.88M | 725.83M | 752.10M | 568.97M |
| Current liabilities | |||||
| Accounts payable | 48.25M | 57.17M | 96.08M | 31.98M | 37.49M |
| Accrued expenses | 149.85M | 111.20M | 107.24M | 73.24M | 33.34M |
| Short term debt | 9.74M | 7.12M | 7.07M | 33.91M | 6.27M |
| Deferred revenue | 5.98M | 5.76M | 11.94M | 10.19M | 19.83M |
| Tax payable | — | — | — | — | — |
| Pensions | 56.39M | 52.46M | 51.86M | 47.16M | 34.69M |
| Other current liabilities | — | — | — | 27.99M | — |
| Non current liabilities | |||||
| Long term debt | 635.06M | 469.00M | 273.40M | 325.87M | 362.53M |
| Provision for risks and charges | — | 45.95M | — | — | — |
| Deferred liabilities | 121.24M | 50.69M | 1.40M | 679,000 | 1.94M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 3.64M | 4.74M | 5.53M | 22.08M | 11.73M |
| Shareholders equity | |||||
| Common stock | 1.15M | 1.02M | 908,000 | 859,000 | 846,000 |
| Retained earnings | -719.19M | -606.15M | -626.78M | -589.18M | -251.96M |
| Other shareholders equity | -1.26M | -1.18M | -362,000 | -278,000 | -234,000 |
| Total shareholders equity | 1.07B | 859.42M | 693.63M | 619.60M | 929.05M |
| Additional paid in capital | 1.81B | 1.49B | 1.34B | 1.23B | 1.17B |
| Treasury stock | 21.12M | 21.12M | 21.12M | 21.12M | — |
| Minority interest | — | — | — | — | 6.69M |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -113.04M | -19.16M | -37.60M | -334.25M | -305.58M | -54.19M | -69.77M | -226.78M | 319.81M | -25.25M | 20.02M |
| Depreciation | 123.42M | 67.20M | 60.04M | 61.48M | 60.91M | 44.52M | 32.37M | 17.22M | 7.17M | — | 1.21M |
| Deferred Taxes | -31.27M | 342,000 | -526,000 | -1.13M | -23.12M | 44,000 | -7.27M | -10.76M | 23.46M | — | — |
| Stock-Based Compensation | 40.50M | 33.98M | 16.71M | 14.61M | 15.62M | 17.61M | 20.44M | 22.50M | 14.73M | — | 91,000 |
| Other Non-Cash Items | 49.19M | 7.41M | 14.45M | 41.41M | 9.53M | 1.50M | 1.80M | 5.29M | -413.96M | 48,000 | -45.42M |
| Accounts Receivable | -170.30M | -110.67M | -24.76M | -58.42M | -16.73M | -24.50M | -11.26M | -11.04M | 11.76M | — | -8.67M |
| Accounts Payable | -6.72M | 13.17M | 7.25M | 3.55M | -5.48M | 7.60M | 5.56M | -6.37M | 2.76M | — | -843,000 |
| Other Assets & Liabilities | 187.92M | 19.74M | -4.95M | -16.59M | 43.60M | -15.40M | -1.54M | 7.73M | -6.54M | 11.05M | 16.71M |
| Operating Cash Flow | 79.70M | 12.00M | 30.61M | -289.35M | -221.25M | -22.82M | -29.66M | -202.21M | -40.81M | -14.15M | -16.90M |
| Investing Activities | |||||||||||
| Capital Expenditures | — | -38.36M | -24.98M | -29.47M | -35.53M | -39.55M | -27.85M | -15.53M | -6.52M | — | -10.44M |
| Net Intangibles | -28.75M | -38.36M | -24.98M | — | — | — | — | — | — | — | — |
| Net Acquisitions | 870,000 | 5.55M | 14.22M | — | -96.06M | -139.60M | -4.82M | -85.56M | 13.07M | — | -15.52M |
| Purchase of Investments | — | — | -3.00M | -11.17M | -11.13M | -10.01M | — | — | -54.23M | — | — |
| Sale of Investments | — | — | 500,000 | 143.44M | 2.58M | 349,000 | 44.21M | 9.38M | 4.00M | — | — |
| Investing Cash Flow | -386.80M | -259.12M | -15.79M | 261.07M | -181.63M | -160.38M | -12.27M | -96.66M | -43.68M | -3.58M | -25.91M |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | 647.49M | 219.74M | — | 30.06M | 62.65M | 167.18M | — | 121.25M | — | — | 23.00M |
| Long-Term Debt Payments | -464.20M | — | -98.85M | -16.61M | — | — | — | — | — | — | — |
| Other Financing Charges | -62.17M | -18.32M | -3.85M | -7.90M | -106.38M | 94.92M | -5.47M | 27.68M | 4.92M | -1.37M | — |
| Financing Cash Flow | 268.82M | 127.09M | -42.84M | -14.44M | -43.73M | 262.10M | 161.48M | 148.93M | 214.01M | -1.37M | 34.29M |
| Other Cash Details | |||||||||||
| End Cash Position | 223.46M | 215.16M | 354.94M | 361.58M | 128.53M | 388.33M | 295.36M | 170.03M | 152.01M | — | — |
| Income Tax Paid | 4.89M | 1.40M | 551,000 | 9.68M | — | — | — | — | — | — | — |
| Interest Paid | 53.59M | 6.27M | 7.11M | 13.35M | — | — | — | — | — | — | — |
| Free Cash Flow | 113.84M | -49.91M | 13.76M | -45.70M | -78.18M | -60.20M | -55.81M | -51.04M | -24.98M | — | -24.07M |
Error: Invalid format in Holders JSON file.
Article
Evolent Health Announces Changes to Board of Directors
Richard " Rick " Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott.
Feb 4, 2025
Article
New Strong Sell Stocks for January 30th
DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024.
Jan 30, 2025
Article
Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025
Company to Participate in Upcoming Conferences WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Jan 27, 2025
